post-cal model adjust increas estim reflect stronger top
initi guidanc
updat estim zoeti follow compani fourth-quart releas
thursday morn februari overal number ahead estim
initi guidanc provid believ top-lin growth come
year exceed market pace roughli thank steadi
innov portfolio breadth across geographi speci
leap faith zoeti new product flow manag acknowledg
one major driver past yearsth dermatolog portfolioi like slow
year continu impress steadi stream innov
suspect continu next two year manag point diagnost
companion anim pain control combin parasiticid antibiot replac
livestock area high potenti maintain outperform rate zoeti given
stabil busi model prospect anoth double-digit earn
light posit quarter better initi guidanc increas
full year ep target target top line commentari
roughli million better prior model commentari sg
leverag also stronger expect expect earn growth
driven tax reform organ revenu growth margin leverag
lesser extent capit deploy
geograph expect unit state grow versu last year
project previous expect intern segment increas
compar last year project previous
observ quarter
return equiti ttm
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
expect dermatolog parasiticid offer diminish growth driver year livestock pick
upparticularli swine busi global expect livestock expand compar off-set
companion anim slow last year previous project companion anim growth
apoquel cytopoint combin million revenu fourth quarter year-over-year increas
sequenti uptick million manag shift sale expectationssuggest expect dermatolog
sale reach million higher compar peak sale commentari million
million see exhibit dermatolog sale apoquel cytopoint million quarter
balanc sale intern market simparica sale continu ramp grow compar
quarter last year believ simparica take share legaci product flea tick market believ
product grow doubl digit stand-alon product upsid potenti flea/tick/heartworm
combin product eventu roll
exhibit quarterli apoquel cytopoint sale present
 livestock busi significantli surpass expect quarter growth compar
estim thank strong cattl placement share gain poultri believ swine busi
struggl last year rebound given product improv estim growth swine compar
growth also estim improv growth poultri compar
pleasantli surpris pharmaq perform quarter year also view potenti
diagnost livestock space potenti add top-lin growth medium long term
although busi invest mode least manag much vocal market
segment past suggest addit product close roll
increas revenu million billion also lift ebit margin
assumpt basi point translat ep estim increas
also increas revenu estim million billion increas
ebit margin basi point ep estim increas
valuat stock thought
follow gain thursday zoeti trade time updat ep estim compar post-
ipo averag time forward earn small-cap anim health peer virbac virp dechra dph
phibro vetoquinol veto averag time higher-growth veterinari peer
abaxi abax outperform time continu
impress manag execut expect time busi model stabil translat
steadi share price improv stabl improv valuat reiter outperform rate summari
revis model found exhibit
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling net incom excl non-recurring non-recurring tax non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
